AXA IM Alts raises 1.9bn European Life Sciences Fund
AXA IM Alts has raised 1.9bn of equity to accelerate investments into the Life Sciences sector.
Synaffix inks $246m deal with ProfoundBio
Synaffix has nonexclusivey licensed its award-winning ADC technologies to Chinese ProfoundBio in an up to $246m deal
Stada und Calliditas Therapeutics in 97,5 Mio. Euro-Deal
Die Stada Arzneimittel AG zahlt im Rahmen eines EU-Marketingabkommens für Nefecon zur Behandlung der IgA-Nephropathie vorab 20 Mio. Euro an die Calliditas Therapeutics AB.
Nanosyrinx raises £6.2m to validate drug delivery platform
Coventry-based NanoSyrinx plc has raised £6.2m in seed financing to develop a new cell engineering tool for novel targeted therapeutic modalities.
Unilever licences Arzeda Inc.s enzyme technology
As part of its ‘Clean Future’ strategy, Unilever NV has licensed enzyme technology from Arzeda Inc. to help rid detergent production of fossil carbon.
Bio-Me raises NOK10m
Oslo-based microbiome expert Bio-Me A/S has raised NOK10m in a new funding round.
Novalis Biotech closes biotech fund at 25m
Cellink AB to take-over Discover Echo Inc
Swedish Cellink AB has announced a bid of $110m to take over all shares of Discover Echo Inc., 11% of which to be paid in newly issued shares.
Rheincell set to be acquired by Catalent
Major CDMO Catalent has swallowed German RheinCell Therapeutics GmbH, an iPSC specialist, to expand its offerings in cell and gene therapies.
Data protection rules may block medical progress
In an effort to ban AI tools for facial recognition, the EU risks to block European medical geneticists to recognise genetic diseases.